 "Shreehas Tambe, managing director and chief executive officer of Biocon Biologics")
After the acquisition of Viatris’ global biosimilars business last year and Serum Institute Life Sciences doubling its investments to $300 million, Biocon Biologics (BBL), a subsidiary of Biocon, is gearing up for an initial public offering (IPO) now. Shreehas Tambe, managing director (MD) and chief executive officer (CEO) of Biocon Biologics talks about the company’s IPO roadmap, investment plans and Viatris integration, in a Zoom interview with Shine Jacob. Edited excerpts:
Serum Institute of India doubled its investment to $300 million in BBL, which is also backed by private equity (PE) investors. What is the plan ahead? How are PEs looking
